ARTICLES BY C. RAJAN
-
Tetraphase's New Antibiotic Succeeds In Phase 3 Study12/26/2014
Antibiotic maker Tetraphase has announced positive top-line results from the Phase 3 clinical trial of its novel antibiotic, eravacycline, for the treatment of complicated intra-abdominal infections (cIAI). The study (IGNITE 1) showed that eravacycline is as effective as Merck’s antibiotic, ertapenem.
-
Researchers Discover New Antibodies Paving Way For Universal Dengue Vaccine12/23/2014
A team of international researchers has made an important discovery that could lead to the development of the first universal dengue vaccine. The researchers, including groups from Australia, Vietnam, and London, have discovered a major new class of antibodies that neutralises all four different types of the deadly dengue virus.
-
Auspex Pharma's Drug For Huntington's Disease Chorea Succeeds In Late-Stage Trials12/23/2014
California-based biopharmaceutical company, Auspex Pharmaceuticals, has announced positive topline efficacy and safety results from two phase 3 trials evaluating its investigational drug, SD-809, for the treatment of chorea associated with Huntington's disease (HD)
-
Researchers Develop Novel Antimicrobial Peptides To Combat 'Superbugs'12/16/2014
Researchers at the University of Pittsburgh’s Center for Vaccine Research (CVR) have developed a set of novel antimicrobial peptides that are more effective than traditional antibiotics at fighting different drug-resistant bacteria, including the notorious "superbugs".
-
PaxVax's Single-Dose Cholera Vaccine Succeeds In Final Phase 3 Study12/15/2014
California based vaccine maker, PaxVax, has announced positive results from the final Phase 3 trial of its single-dose oral cholera vaccine candidate, PXVX0200.
-
Antibiotic Giant Cubist Acquired by Merck In $9.5 B Deal12/11/2014
Massachusetts-based company Cubist Pharmaceuticals has announced that Merck will be acquiring Cubist in a deal valued at about $9.5 billion.
-
Researchers Identify New Class Of Antimalarial Agents12/8/2014
Researchers have found a new class of molecules that is highly potent against the human malaria parasites and causes the parasites’ guts to swell up and explode, CBS News reported.
-
FDA Grants Orphan-Drug Designation To Actinium's AML Drug12/8/2014
New York-based radiotherapy company, Actinium Pharmaceuticals, has announced that the US. FDA has granted orphan-drug designation for Actimab-A, an alpha radioisotope-labeled antibody being developed for newly diagnosed AML in patients over the age of 60.
-
![breast cancer ribbon]( "New Breast Cancer Vaccine Shows Promise In Initial Trial")
New Breast Cancer Vaccine Shows Promise In Initial Trial12/4/2014Researchers at the Washington University School of Medicine in St. Louis have developed a new breast cancer vaccine, which has shown promising results in an initial clinical trial
-
![cancer cells 450x300]( "Researchers Reveal How Immune System “Sees” Tumors")
Researchers Reveal How Immune System “Sees” Tumors12/3/2014Researchers at the Memorial Sloan Kettering Cancer Centre (MSKCC) in New York have made an important breakthrough in understanding how the body’s immune system recognizes tumor cells, possibly leading to a new generation of improved immunotherapies.
-
![hands pointing at chart 450x300]( "New Acute Myeloid Leukemia Drug Shows Positive Phase 1 Trial Results")
New Acute Myeloid Leukemia Drug Shows Positive Phase 1 Trial Results12/3/2014Scientists at the University of Colorado Cancer Center have announced the "extremely promising" results from a phase 1 clinical trial for investigational drug AG-120 in acute myeloid leukemia (AML) patients with IDH1 gene mutations.
-
![keyboard]( "Researchers Make Breakthrough Discovery Paving Way For New MS Treatments")
Researchers Make Breakthrough Discovery Paving Way For New MS Treatments12/2/2014Researchers at the National University of Singapore (NUS) have discovered a new type of immune cells that play an important role in multiple sclerosis (MS) and other inflammatory diseases, thus providing a new avenue for therapies for these diseases.
-
![Malaria 450x300]( "First Chikungunya Vaccine Succeeds In Phase 1 Study")
First Chikungunya Vaccine Succeeds In Phase 1 Study11/25/2014Vienna-based biotech company, Themis Bioscience, has announced the positive results from a phase 1 clinical study of its prophylactic Chikungunya fever vaccine candidate.
-
![brain research challenges 450x300]( "Celldex's Brain Cancer Vaccine Shows Promising Interim Results")
Celldex's Brain Cancer Vaccine Shows Promising Interim Results11/24/2014New Jersey-based biotech company Celldex Therapeutics has reported the positive interim results from a Phase 2 study of its novel brain cancer immunotherapy vaccine, rindopepimut, in patients with recurrent glioblastoma.
-
![Brain 450x300]( "Global Coalition Formed For Accelerating Drug Development For Brain Diseases")
Global Coalition Formed For Accelerating Drug Development For Brain Diseases11/21/2014A new coalition of nine charities and funding bodies has been formed to revive the development of promising drug candidates for neurodegenerative brain diseases — an initiative jumpstarted with roughly £30 million ($47 million) in funding.
